• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.


Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
Application Number P000008 S017
Current Protocol Accepted 03/03/2016
Study Name OSB Lead-Apollo-001
Study Status Progress Inadequate
Study Progress Reason Site enrollment milestones not met, Subject enrollment milestones not met
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) No
Data Source New Data Collection
Comparison Group Device Subjects Serve as Own Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description New enrollment study designed to evaluate the safety and effectiveness of

Lap-Band. Prospective single-arm cohort.

  show the rest ...
Study Population Description Patients with BMI >=30 kg/m2 and <40 kg/m2 and 1 or more obesity-

related comorbidities. There   show the rest ...
Sample Size 325 subjects will be enrolled across 20 U.S. sites. Assuming 20% attrition, a sample size   show the rest ...
Data Collection Primary safety endpoint: 5-year explant rate; Secondary effectiveness

endpoints: 5-year responder rate (where response is defined   show the rest ...
Followup Visits and Length of Followup 10 Years - In-office visits before and after surgery, at 1, 2, 3, and 6   show the rest ...

OSB Lead-Apollo-001 Schedule

Report Schedule
Date Due
FDA Receipt
Reporting Status
six month report 08/17/2011 11/25/2011 Overdue/Received
one year report 02/16/2012 02/15/2012 On Time
18 month report 08/16/2012 08/17/2012 Overdue/Received
two year report 02/15/2013 02/13/2013 On Time
Interim Progress Report 08/14/2013 08/14/2013 On Time
three year report 02/15/2014 03/13/2014 Overdue/Received
six month report 03/24/2015 03/26/2015 Overdue/Received
one year Report 09/24/2015 10/16/2015 Overdue/Received
18 month report 03/24/2016 03/25/2016 Overdue/Received
two year report 09/24/2016    

Show All Studies